Efficacy of treatment with faricimab for patients with refractory nAMD.

ObjectiveTo investigate the efficacy of treatment with faricimab in patients with refractory neovascular age-related macular degeneration (nAMD).MethodsA Single-centre, retrospective cohort study was conducted on patients treated with faricimab for refractory nAMD. Outcome measures comprised best measured visual acuity (BMVA), central foveal thickness (CFT) on optical coherence tomography (OCT) and mean treatment interval for patients receiving six or more faricimab injections.ResultsCFT was shown to significantly decrease for all eyes ( = 52) treated with six faricimab injections (χ 52.88 df 5  < 0.001) from baseline (274 ± 73 µm) and subsequent injections (244 ± 59 µm). BMVA remained stable (χ 6.45 df 5  = 0.26) from baseline treatment (baseline, 67 letters ± 13) and subsequent injections with faricimab (67 letters ± 14, injection 6). Mean treatment interval with faricimab increased from 4.2 weeks to 5.8 weeks indicating sustained results. Zero cases of post-operative complications were reported.ConclusionThis study adds to the growing body of real-world evidence supporting the efficacy of faricimab in treating refractory nAMD. With improvements in anatomical outcomes and an extended treatment interval, whilst maintaining stable vision, faricimab emerges as a promising therapeutic option for patients with refractory nAMD.